72,212 results match your criteria Lung Cancer Oat Cell Small Cell


The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies.

Brain 2019 Apr 22. Epub 2019 Apr 22.

Department of Neurology, Erasmus Medical Center, Dr. Molewaterplein 40, GD, Rotterdam, The Netherlands.

In this study we report the clinical features of 32 patients with gamma aminobutyric acid B receptor (GABABR) antibodies, identify additional autoantibodies in patients with anti-GABABR encephalitis that mark the presence of an underlying small cell lung carcinoma and optimize laboratory methods for the detection of GABABR antibodies. Patients (n = 3225) were tested for the presence of GABABR antibodies using cell-based assay, immunohistochemistry and live hippocampal neurons. Clinical data were obtained retrospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/brain/awz094DOI Listing

The circRNA circP4HB promotes NSCLC aggressiveness and metastasis by sponging miR-133a-5p.

Biochem Biophys Res Commun 2019 Apr 17. Epub 2019 Apr 17.

Anhui Clinical and Preclinical Key Laboratory of Respiratory Disease, Department of Respiration, First Affiliated Hospital, Bengbu Medical College, Bengbu, Anhui Province, China. Electronic address:

Background: Non-small cell lung carcinoma (NSCLC) continues to top the list of cancer mortalities worldwide. The role of circular RNAs (circRNAs) in tumorigenesis has been increasingly appreciated, although it is relatively unexplored in NSCLC. Herein, we report on the role of circP4HB in NSCLC. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0006291X193075
Publisher Site
http://dx.doi.org/10.1016/j.bbrc.2019.04.108DOI Listing
April 2019
2 Reads

Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma.

Radiother Oncol 2019 May 1;134:44-49. Epub 2019 Feb 1.

Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, USA.

Purpose: Although stereotactic body radiation therapy (SBRT) is the standard of care for inoperable early-stage non-small cell lung carcinoma (NSCLC), its role for medically operable patients remains controversial. To address this knowledge gap, we conducted a multi-institutional study to assess post-SBRT disease control and survival outcomes in medically operable patients.

Methods: We conducted a retrospective cohort study including patients with biopsy-proven cT1-2N0M0 NSCLC treated with definitive SBRT (2006-2015). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2019.01.027DOI Listing

A Psoriasiform Drug Eruption Secondary to Nivolumab for Hepatocellular Carcinoma: a Case Report.

Hepatology 2019 Apr 20. Epub 2019 Apr 20.

Corporal Michael J Crescenz VA Medical Center, Pathology, 3900 Woodland Avenue, Philadelphia, Pennsylvania, United States.

Nivolumab, an immune checkpoint inhibitor that acts by preventing programmed-death ligand 1 (PD-L1) from binding to the programmed cell death protein-1 (PD-1) receptor, is utilized to treat a variety of cancers including renal cell carcinoma, non-small cell lung cancer, and metastatic melanoma. Currently, nivolumab is FDA-approved as a second-line treatment for advanced hepatocellular carcinoma (HCC) after showing efficacy in patients who progressed on or were intolerant to sorafenib. This article is protected by copyright. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/hep.30659
Publisher Site
http://dx.doi.org/10.1002/hep.30659DOI Listing
April 2019
1 Read

Multi-subtype classification model for non-small cell lung cancer based on radiomics: SLS model.

Med Phys 2019 Apr 19. Epub 2019 Apr 19.

Beijing Advanced Innovation Center for Biomedical Engineering, Beihang University, Beijing, 100083, China.

Purpose: Histological subtypes of non-small cell lung cancer (NSCLC) are crucial for systematic treatment decisions. However, the current studies which used non-invasive radiomic methods to classify NSCLC histology subtypes mainly focused on two main subtypes: squamous cell carcinoma (SCC) and adenocarcinoma (ADC), while multi-subtype classifications that included the other two subtypes of NSCLC: large cell carcinoma (LCC) and not otherwise specified (NOS), were very few in the previous studies. The aim of this work is to establish a multi-subtype classification model for the four main subtypes of NSCLC and improve the classification performance and generalization ability compared with previous studies. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/mp.13551
Publisher Site
http://dx.doi.org/10.1002/mp.13551DOI Listing
April 2019
2 Reads

PD1/PD-L1 inhibitor treatment for late stage non-small cell lung carcinoma, sometimes…does more harm than good!

Authors:
Paul Hofman

J Thorac Dis 2019 Mar;11(Suppl 3):S396-S398

Laboratory of Clinical and Experimental Pathology, Université Côte d'Azur, CHU Nice, FHU OncoAge, Pasteur Hospital, Nice, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.11.140DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424771PMC

Development of Hepatocellular Carcinoma During Nivolumab Treatment for Recurrent Non-Small Cell Lung Cancer: A Case Report.

Tohoku J Exp Med 2019 04;247(4):247-250

Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital.

Nivolumab, a monoclonal antibody targeting programmed cell death 1 (PD-1), is the standard second-line therapy for advanced non-small cell lung cancer (NSCLC). In the current immunotherapy era, it is often difficult to evaluate the therapeutic effect, disease progression, and pseudo-enlargement of the tumor or the emergence of another etiology. In the present report, we describe a 79-year-old patient with hepatocellular carcinoma (HCC) newly detected during nivolumab treatment for recurrent NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1620/tjem.247.247DOI Listing

Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer.

Oncol Res Treat 2019 Apr 17;42(5):243-254. Epub 2019 Apr 17.

Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.

Background: Anti-PD1 monoclonal antibody nivolumab is an approved therapy option for the treatment of advanced squamous cell non-small cell lung cancer (SQ-NSCLC) patients. Data outside clinical trials about therapy efficacy and safety in later therapy line treatments have rarely been described until now.

Methods: We performed a retrospective data analysis of patients who were enrolled into the nivolu-mab Compassionate Use Program (CUP) in Germany. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499321DOI Listing
April 2019
2 Reads

New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.

Int J Biol Markers 2019 Apr 17:1724600819834235. Epub 2019 Apr 17.

5 Division of Laboratory Medicine, Humanitas Clinical and Research Center, IRCCS, Rozzano Milan, Italy.

Background: Testing for circulating biomarkers in lung cancer is hampered by the insufficient specificity. We aimed to assess the relative diagnostic accuracy of pro-gastrin-releasing peptide (ProGRP) for the differential diagnosis of small cell lung cancer and compare it with more conventional biomarkers.

Methods: We enrolled a cohort of 390 patients with a clinical suspicion of lung cancer and for whom a histologic assessment was available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1724600819834235DOI Listing

MAPK pathway: a potential target for the treatment of non-small-cell lung carcinoma.

Future Med Chem 2019 Apr 17. Epub 2019 Apr 17.

Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo NSW 2007, Australia.

View Article

Download full-text PDF

Source
https://www.future-science.com/doi/10.4155/fmc-2018-0468
Publisher Site
http://dx.doi.org/10.4155/fmc-2018-0468DOI Listing
April 2019
2 Reads

Image-guided Fine Needle Aspiration Cytology of Intrathoracic Lesions.

J Cytol 2019 Apr-Jun;36(2):106-110

Department of Pulmonary Medicine, Kasturba Medical College, Manipal Academy of Higher Education, Mangalore, Karnataka, India.

Background: Percutaneous, image-guided transthoracic fine needle aspiration cytology (TTFNAC) is a rapid, yet accurate, and well-established diagnostic method used in the cytological evaluation of intrathoracic lesions. The study was done to determine the utility of image-guided TTFNAC in diagnosis of intrathoracic lesions.

Subjects And Methods: A retrospective analysis of all cases who underwent image-guided TTFNAC of a suspected intrathoracic lesion, in a tertiary care hospital was done over a period of 3 years. Read More

View Article

Download full-text PDF

Source
http://www.jcytol.org/text.asp?2019/36/2/106/251452
Publisher Site
http://dx.doi.org/10.4103/JOC.JOC_187_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425786PMC
April 2019
1 Read

Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients.

Nat Commun 2019 Apr 16;10(1):1772. Epub 2019 Apr 16.

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, 510080, Guangzhou, China.

Deep understanding of the genomic and immunological differences between Chinese and Western lung cancer patients is of great importance for target therapy selection and development for Chinese patients. Here we report an extensive molecular and immune profiling study of 245 Chinese patients with non-small cell lung cancer. Tumor-infiltrating lymphocyte estimated using immune cell signatures is found to be significantly higher in adenocarcinoma (ADC, 72. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-019-09762-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467893PMC
April 2019
2 Reads

Does the use of postoperative low-molecular-weight heparin in patients with lung cancer increase tube drainage?

Asian J Surg 2019 Apr 13. Epub 2019 Apr 13.

Department of Thoracic Surgery, Sakarya University, Faculty of Mecidine, Sakarya, Turkey. Electronic address:

Background: The objectives of this study are to assess the chest drainage volumes of patients undergoing anatomic resection of non-small cell lung carcinoma and to determine the safety and effectiveness of administering enoxaparin for thromboprophylaxis.

Methods: A total of 77 patients were included in the study. A study was conducted on the first group of 42 patients in which enoxaparin prophylaxis (enoxaparin, 40 mg) was subcutaneously injected once a day for a period of three days after the patients underwent anatomic pulmonary resection between March 2016 and March 2018. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10159584193014
Publisher Site
http://dx.doi.org/10.1016/j.asjsur.2019.03.008DOI Listing
April 2019
1 Read

Brain metastases in patients with neuroendocrine neoplasms: risk factors and outcome.

BMC Cancer 2019 Apr 16;19(1):362. Epub 2019 Apr 16.

Department of Gastroenterology and Endocrinology, University Hospital Marburg, Baldinger Strasse, 35043, Marburg, Germany.

Background: Brain metastases (BM) are rarely reported in patients with neuroendocrine carcinoma (NEC) of non-lung origin and neuroendocrine tumors (NET) of the gastroenteropancreatic (GEP) or bronchopulmonary system. However, symptomatic brain metastases are associated with dismal prognosis, so early detection and treatment could be advisable.

Methods: We retrospectively analyzed 51 patients with GEP-NEN and bronchopulmonary NEN excluding small cell lung cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5559-7DOI Listing
April 2019
1 Read

Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.

Eur J Cancer 2019 Apr 13;113:87-95. Epub 2019 Apr 13.

Department of Oncology, University of Oxford, Oxford, United Kingdom; Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom. Electronic address:

Background: Pre-clinically, phosphoinositide 3-kinase (PI3K) inhibition radiosensitises tumours by increasing intrinsic radiosensitivity and by reducing tumour hypoxia. We assessed whether buparlisib, a class 1 PI3K inhibitor, can be safely combined with radiotherapy in patients with non-small cell lung carcinoma (NSCLC) and investigated its effect on tumour hypoxia.

Methods: This was a 3 + 3 dose escalation and dose expansion phase I trial in patients with advanced NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.03.015DOI Listing
April 2019
1 Read

Detection of NRG1 gene fusions in solid tumors.

Clin Cancer Res 2019 Apr 15. Epub 2019 Apr 15.

Medical Oncology, Georgetown University

Background: NRG1 gene fusions are rare but potentially actionable oncogenic drivers present in some solid tumors. Details regarding the incidence of these gene rearrangements are lacking. Here, we assessed the incidence of NRG1 fusions across multiple tumor types and described fusion partners. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-0160DOI Listing
April 2019
1 Read

Amplification of USP13 drives non-small cell lung cancer progression mediated by AKT/MAPK signaling.

Biomed Pharmacother 2019 Apr 12;114:108831. Epub 2019 Apr 12.

The Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, PR China. Electronic address:

USP13 is emerging as a potential target in cancer therapy. However, the effect of USP13 on tumor progression is controversial. Here we focused on non-small cell lung cancer (NSCLC), a common cancer with high mortality, and studied the role of USP13 in tumor growth. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2019.108831DOI Listing
April 2019
1 Read
2.023 Impact Factor

Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry.

PLoS One 2019 15;14(4):e0215393. Epub 2019 Apr 15.

Precision Medicine Laboratories, Precision Medicine and Genomics, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Cambridge, United Kingdom.

Four immunohistochemistry (IHC) diagnostic assays have been approved for tumour PD-L1 protein assessment in the clinic. However, mRNA detection by in situ hybridisation (ISH) could be utilised as an alternative to protein detection. Detecting spatial changes in gene expression provides vital prognostic and diagnostic information, particularly in immune oncology where the phenotype, cellular infiltration and immune activity status may be associated with patient survival. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0215393PLOS
April 2019
1 Read

Dermatomyositis associated with adenocarcinoma of the lung: A case report.

J Family Med Prim Care 2019 Feb;8(2):754-756

Department of Psychiatry, Iqraa International Hospital and Research Centre, Calicut, Kerala, India.

The association of dermatomyositis and underlying malignancies, especially small cell and squamous cell carcinoma of the lung, has been recognized a long time ago. We report the case of a 63-year-old male chronic smoker with adenocarcinoma lung associated with dermatomyositis. The occurrence of dermatomyositis should be considered as a potential presentation of paraneoplastic syndromes and physicians encountering similar clinical situations should perform extensive diagnostic work-up to exclude underlying neoplastic lesions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jfmpc.jfmpc_467_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436299PMC
February 2019
1 Read

Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy.

Front Oncol 2019 29;9:199. Epub 2019 Mar 29.

Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.

There is increasing use of immune checkpoint blockade (ICB) across multiple cancer types, including in patients at risk for vertebral metastases and cord compression. These patients are often treated with palliative radiotherapy (PRT); however, data evaluating the combination of PRT and ICB in patients with vertebral metastases is limited. Furthermore, patients with cord compression are generally excluded from prospective clinical trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00199DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450051PMC
March 2019
2 Reads

Characterization of Distinct Populations of Carcinoma-Associated Fibroblasts from Non-Small Cell Lung Carcinoma Reveals a Role for ST8SIA2 in Cancer Cell Invasion.

Neoplasia 2019 Apr 9;21(5):482-493. Epub 2019 Apr 9.

Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada. Electronic address:

Carcinoma-associated fibroblasts (CAFs) are abundant stromal cells in tumor microenvironment that are critically involved in cancer progression. Contrasting reports have shown that CAFs can have either pro- or antitumorigenic roles, indicating that CAFs are functionally heterogeneous. Therefore, to precisely target the cancer-promoting CAF subsets, it is necessary to identify specific markers to define these subpopulations and understand their functions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2019.03.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458340PMC
April 2019
2 Reads

The landscape of actionable molecular alterations in immunomarker-defined large cell carcinoma of lung.

J Thorac Oncol 2019 Apr 9. Epub 2019 Apr 9.

Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, the Chinese University of Hong Kong, Hong Kong; Li Ka-Shing Institute of Health Sciences, Sir Y.K. Pao Cancer Center, the Chinese University of Hong Kong, Hong Kong; Institute of Digestive Disease, State Key Laboratory of Digestive Disease, the Chinese University of Hong Kong, Hong Kong. Electronic address:

Introduction: Patients with pulmonary large cell carcinoma (LCC) have poor prognosis and limited treatment option. The identification of clinically actionable molecular alterations helps to guide personalized cancer treatment decisions.

Patients And Methods: A consecutive cohort of 789 resected non-small cell lung carcinomas (NSCLCs) were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.03.021DOI Listing
April 2019
1 Read

Metastatic lung cancer associated with Warthin's tumour.

Niger J Clin Pract 2019 Apr;22(4):585-587

Department of Pulmonary Diseases, Health Sciences University Bursa Yuksek Ihtisas Education and Research Hospital, Bursa, Turkey.

Warthin's tumors which can easily be subjected to misinterpretation are encountered commonly in clinical practice. Warthin's tumors which generally have the localization of parotid gland cauda and have a slow growing characteristic can rarely be seen aside from parotid gland; such as cervical lymph nodes and minor salivary glands. A 56-year-old patient's case that comprised atypical coexistence of Warthin tumor with PET/CT scan positive cervical lymph nodes during the diagnostic examination carried out for a pulmonary mass lesion is presented. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/njcp.njcp_424_18DOI Listing
April 2019
1 Read

Farnesoid X receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXRhighPD-L1low NSCLC to Anti-PD-1 Immunotherapy.

Cancer Immunol Res 2019 Apr 11. Epub 2019 Apr 11.

Department of Respiratory Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

The farnesoid X receptor (FXR) regulates inflammation and immune responses in a subset of immune-mediated diseases. We previously reported that FXR expression promotes tumor cell proliferation in non-small cell lung cancer (NSCLC). Here we study the relevance of FXR to the immune microenvironment of NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-17-0672DOI Listing
April 2019
1 Read

Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer.

J Exp Clin Cancer Res 2019 Apr 11;38(1):157. Epub 2019 Apr 11.

Affiliated Cancer Hospital and institute of Guangzhou Medical University; Key Laboratory of Protein Modification and Degradation; State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 511436, Guangdong, China.

Background: Prostate cancer (PCa) remains a challenge worldwide. Due to the development of castration-resistance, traditional first-line androgen deprivation therapy (ADT) became powerlessness. Epidermal growth factor receptor (EGFR) is a well characterized therapeutic target to treat colorectal carcinoma and non-small cell lung cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-019-1165-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460657PMC
April 2019
7 Reads

Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.

Thorac Cancer 2019 Apr 10. Epub 2019 Apr 10.

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

SMARCA4 is a subunit of the switch/sucrose non-fermentable (SWI/SNF) chromatin-remodeling complex. An effective treatment for SMARCA4-deficient non-small cell lung carcinoma (NSCLC) has not yet been established. Correlations between a response to immune checkpoint inhibitors and the SWI/SNF complex have been suggested, but little is known about the efficacy of immune checkpoint inhibitors against SMARCA4-deficient NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.13070DOI Listing
April 2019
1 Read

Repurposing vitamin D for treatment of human malignancies targeting tumor microenvironment.

Acta Pharm Sin B 2019 Mar 6;9(2):203-219. Epub 2018 Sep 6.

Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.

Tumor cells along with a small proportion of cancer stem cells exist in a stromal microenvironment consisting of vasculature, cancer-associated fibroblasts, immune cells and extracellular components. Recent epidemiological and clinical studies strongly support that vitamin D supplementation is associated with reduced cancer risk and favorable prognosis. Experimental results suggest that vitamin D not only suppresses cancer cells, but also regulates tumor microenvironment to facilitate tumor repression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.apsb.2018.09.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437556PMC
March 2019
1 Read

Identification of monotonically differentially expressed genes for non-small cell lung cancer.

Authors:
Suyan Tian

BMC Bioinformatics 2019 Apr 11;20(1):177. Epub 2019 Apr 11.

Division of Clinical Research, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, Jilin, China.

Background: Monotonically expressed genes (MEGs) are genes whose expression values increase or decrease monotonically as a disease advances or time proceeds. Non-small cell lung cancer (NSCLC) is a multistage progression process resulting from genetic sequences mutations, the identification of MEGs for NSCLC is important.

Results: With the aid of a feature selection algorithm capable of identifying MEGs - the MFSelector method - two sets of potential MEGs were selected in this study: the MEGs across the different pathologic stages and the MEGs across the risk levels of death for the NSCLC patients at early stages. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12859-019-2775-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458730PMC
April 2019
1 Read

Estimating the Survival of Patients With Lung Cancer: What Is the Best Statistical Model?

J Prev Med Public Health 2019 Mar 18;52(2):140-144. Epub 2019 Feb 18.

Health Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran.

Objectives: Investigating the survival of patients with cancer is vitally necessary for controlling the disease and for assessing treatment methods. This study aimed to compare various statistical models of survival and to determine the survival rate and its related factors among patients suffering from lung cancer.

Methods: In this retrospective cohort, the cumulative survival rate, median survival time, and factors associated with the survival of lung cancer patients were estimated using Cox, Weibull, exponential, and Gompertz regression models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3961/jpmph.17.090DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459760PMC
March 2019
1 Read

Tumor growth suppression using a combination of taxol-based therapy and GSK3 inhibition in non-small cell lung cancer.

PLoS One 2019 10;14(4):e0214610. Epub 2019 Apr 10.

School of Biochemistry, Medical Sciences Building, University of Bristol, Bristol, United Kingdom.

Glycogen synthase kinase-3 (GSK3) is over-expressed and hyperactivated in non-small cell lung carcinoma (NSCLC) and plays a role in ensuring the correct alignment of chromosomes on the metaphase plate during mitosis through regulation of microtubule stability. This makes the enzyme an attractive target for cancer therapy. We examined the effects of a selective cell-permeant GSK3 inhibitor (CHIR99021), used alone or in combination with paclitaxel, using an in vitro cell growth assay, a quantitative chromosome alignment assay, and a tumor xenograft model. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0214610PLOS
April 2019
1 Read

Runx3 inhibits endothelial progenitor cell differentiation and function via suppression of HIF-1α activity.

Int J Oncol 2019 Feb 11. Epub 2019 Feb 11.

BK21 Plus KNU Multi-Omics Creative Drug Research Team, Kyungpook National University, Daegu 41566, Republic of Korea.

Endothelial progenitor cells (EPCs) are bone marrow (BM)‑derived progenitor cells that can differentiate into mature endothelial cells, contributing to vasculogenesis in the blood vessel formation process. Runt‑related transcription factor 3 (RUNX3) belongs to the Runt domain family and is required for the differentiation of specific immune cells and neurons. The tumor suppressive role of RUNX3, via the induction of apoptosis and cell cycle arrest in a variety of cancers, and its deletion or frequent silencing by epigenetic mechanisms have been studied extensively; however, its role in the differentiation of EPCs is yet to be investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2019.4713DOI Listing
February 2019
1 Read
3.025 Impact Factor

Hsp70-Activated NK Cells in Combination With PD-1 Inhibition Significantly Increase Overall Survival in Preclinical Models of Glioblastoma and Lung Cancer.

Front Immunol 2019 22;10:454. Epub 2019 Mar 22.

Radiation Immuno-Oncology, Center for Translational Cancer Research, TUM (TranslaTUM), Munich, Germany.

Heat shock protein 70 (Hsp70) which is expressed on the plasma membrane of highly aggressive tumors including non-small cell lung carcinoma and glioblastoma multiforme serves as a target for Hsp70-targeting NK cells. Herein, we aimed to investigate the antitumor effects of a combined therapy consisting of Hsp70-peptide TKD/IL-2-activated NK cells in combination with mouse/human anti-PD-1 antibody in a syngeneic glioblastoma and a xenograft lung cancer mouse model. Mice with membrane Hsp70 positive syngeneic GL261 glioblastoma or human xenograft A549 lung tumors were sham-treated with PBS or injected with TKD/IL-2-activated mouse/human NK cells and mouse/human PD-1 antibody either as a single regimen or in combination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00454DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439337PMC
March 2019
2 Reads

JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells.

Oncogene 2019 Apr 9. Epub 2019 Apr 9.

Department of Cell & Molecular Medicine, Rush University Medical Center, Chicago, IL, 60612, USA.

Platinum-based drugs such as cisplatin (CP) are the first-line chemotherapy for non-small-cell lung carcinoma (NSCLC). Unfortunately, NSCLC has a low response rate to CP and acquired resistance always occurs. Histone methylation regulates chromatin structure and is implicated in DNA repair. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-019-0814-6DOI Listing
April 2019
1 Read

Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.

JAMA 2019 04;321(14):1391-1399

Foundation Medicine Inc, Cambridge, Massachusetts.

Importance: Data sets linking comprehensive genomic profiling (CGP) to clinical outcomes may accelerate precision medicine.

Objective: To assess whether a database that combines EHR-derived clinical data with CGP can identify and extend associations in non-small cell lung cancer (NSCLC).

Design, Setting, And Participants: Clinical data from EHRs were linked with CGP results for 28 998 patients from 275 US oncology practices. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2019.3241DOI Listing
April 2019
2 Reads

The Evolving Uses of "Real-World" Data.

JAMA 2019 04;321(14):1359-1360

Associate Editor.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2019.4064DOI Listing
April 2019
1 Read

Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors.

J Natl Compr Canc Netw 2019 Apr;17(4):297-301

aDivision of Hematology/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento.

Histologic transformation from adenocarcinoma to squamous cell carcinoma in lung cancer has not been reported as a mechanism of resistance to ALK inhibition. This report describes the clinical course of a female former light smoker with metastatic lung adenocarcinoma whose tumor underwent histologic transformation from a well-differentiated lung adenocarcinoma to a well-differentiated lung squamous cell carcinoma in the same location at the left mainstem bronchus while maintaining the ALK fusion oncogene without any resistance mutations. After experiencing disease progression while on crizotinib, the patient participated in clinical trials that provided early access to the novel ALK inhibitors ceritinib and alectinib before they were commercially available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.7291DOI Listing
April 2019
6 Reads

P40 expression in small cell lung cancer: The presence of p40-positive cells does not always indicate squamous differentiation.

Thorac Cancer 2019 Apr 7. Epub 2019 Apr 7.

Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.

Background: Small cell lung cancer (SCLC) is normally diagnosed with hematoxylin and eosin stains, although some cases require immunohistochemistry (IHC). P40 is highly sensitive and specific for squamous cell carcinoma and is thus considered the best marker for this cancer. However, the status of p40 expression in SCLC is not well known. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.13062DOI Listing
April 2019
1 Read

An immunogenic NSCLC microenvironment is associated with favorable survival in lung adenocarcinoma.

Oncotarget 2019 Mar 5;10(19):1840-1849. Epub 2019 Mar 5.

NantOmics LLC, Culver City, CA 90232, USA.

The tumor microenvironment consists of an intricately organized system through which immune cells and cancer cells may communicate to regulate anti-tumor immunogenicity. To this end, non-small cell lung cancer (NSCLC) has been shown to activate a variety of immunological mechanisms, thereby broadening our understanding of lung cancer immunobiology. However, while recent work has highlighted the importance of NSCLC immunology and prognosis, studies have not yet examined the tumor microenvironment (TME) globally in regards to the survival outcomes between two major NSCLC subtypes: lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26748DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442995PMC
March 2019
5 Reads

Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer development.

Oncotarget 2019 Mar 5;10(19):1760-1774. Epub 2019 Mar 5.

Biomedical Data Science Department, Dartmouth College, Hanover, NH, USA.

The development of cancer is driven by the accumulation of many oncogenesis-related genetic alterations and tumorigenesis is triggered by complex networks of involved genes rather than independent actions. To explore the epistasis existing among oncogenesis-related genes in lung cancer development, we conducted pairwise genetic interaction analyses among 35,031 SNPs from 2027 oncogenesis-related genes. The genotypes from three independent genome-wide association studies including a total of 24,037 lung cancer patients and 20,401 healthy controls with Caucasian ancestry were analyzed in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26678DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442994PMC
March 2019
1 Read
6.359 Impact Factor

[Diagnosis of lung biopsy employing the 2015 WHO criteria and detection of related oncogenic driver mutations].

Zhonghua Bing Li Xue Za Zhi 2019 Apr;48(4):270-275

Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

The diagnostic criteria of lung biopsy specimens by 2015 WHO lung tumor classification were used to evaluate lung biopsy specimens along with detection of genetic alterations of major tumor driving genes including epidermal growth factor receptor (EGFR). The clinical data, histological slides, immunohistochemical stains and special stains of 806 lung biopsy specimens at Beijing Hospital from July 2015 to July 2018 were retrospectively analyzed. Diagnosis of lung cancer was reclassified according to the 2015 WHO lung tumor classification and related gene mutation data were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0529-5807.2019.04.002DOI Listing
April 2019
3 Reads

Glucose transporter 3 gene variant is associated with survival outcome of patients with non-small cell lung cancer after surgical resection.

Gene 2019 Apr 4;703:58-64. Epub 2019 Apr 4.

Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea; BK21 Plus KNU Biomedical Convergence Program, Department of Biomedical Science, Kyungpook National University, Daegu, Republic of Korea; Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea; Lung Cancer Center, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea; Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. Electronic address:

This study was conducted to explore whether polymorphisms of glucose transporter 3 (GLUT3) gene affect the prognosis of patients with non-small cell lung cancer (NSCLC) after surgical resection. Four single nucleotide polymorphisms (SNPs) in GLUT3 were investigated in a total of 782 patients with NSCLC who underwent curative surgery. The association of the SNPs with overall survival (OS) and disease free survival (DFS) was analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gene.2019.04.013DOI Listing
April 2019
3 Reads

The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients.

Cell Mol Life Sci 2019 Apr 5. Epub 2019 Apr 5.

Department of Genetics and Clinical Immunology, National Research Institute of Tuberculosis and Lung Diseases, 26 Plocka St., 01-138, Warsaw, Poland.

MicroRNAs (miRNAs), key regulators of gene expression at the post-transcriptional level, are grossly misregulated in some human cancers, including non-small-cell lung carcinoma (NSCLC). The aberrant expression of specific miRNAs results in the abnormal regulation of key components of signalling pathways in tumour cells. MiRNA levels and the activity of the gene targets, including oncogenes and tumour suppressors, produce feedback that changes miRNA expression levels and indicates the cell's genetic activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00018-019-03089-2DOI Listing
April 2019
1 Read

Postoperative C-reactive Protein Is a Predictive Biomarker for Survival After Non-small Cell Lung Cancer Resection.

Anticancer Res 2019 Apr;39(4):2193-2198

Department of Thoracic Surgery, Chubu Rosai Hospital, Nagoya, Japan.

Background/aim: Preoperative C-reactive protein (CRP) is well recognized as a prognostic factor of non-small cell lung cancer (NSCLC). The present study aimed to elucidate the prognostic impact of postoperative CRP in patients with NSCLC following lung resection.

Patients And Methods: We retrospectively reviewed 336 patients with NSCLC treated with lung resection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13334DOI Listing
April 2019
1 Read

Association of Low Body Mass Index With Poor Clinical Outcomes After Resection of Non-small Cell Lung Cancer.

Anticancer Res 2019 Apr;39(4):1987-1996

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Background/aim: This study was performed to evaluate the influence of the body mass index (BMI) on disease-free survival and overall survival (DFS and OS) in patients with resected non-small cell lung cancer (NSCLC).

Patients And Methods: Overall, 546 of 780 (70%) patients with stage I to III NSCLC who underwent surgical resection were randomly selected. The patients were subdivided into three groups: low BMI (<18. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13309DOI Listing
April 2019
1 Read

Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor.

Anticancer Res 2019 Apr;39(4):1923-1926

Kennedy Medical Campus, Sewell, NJ, U.S.A.

Case Report: Case 1 of an investigator-initiated study using oral single agent mifepristone to halt stage IV non-small cell lung cancer whose tumor was devoid of any targeted markers has remained ECOG zero and in good health for over 3 years. Case 2, reported here, is a 68-year-old woman with stage IV non-small cell lung cancer whose tumor was positive for the programmed death ligand-1 (PD-L1) marker. Her cancer progressed despite treatment with a check-point inhibitor (nivolumab), besides 3 rounds of multi-agent chemotherapy. Read More

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.13
Publisher Site
http://dx.doi.org/10.21873/anticanres.13301DOI Listing
April 2019
4 Reads

Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.

Anticancer Res 2019 Apr;39(4):1767-1775

Department of Thoracic, Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Background: The 90-kDa heat-shock protein (HSP90) is a chaperone protein expressed at high levels in cancer cells and is involved in the folding or stabilization of several client proteins, including epidermal growth factor receptor (EGFR). Ganetespib is a second-generation HSP90 inhibitor with a potent antitumor effect against various cancer types.

Materials And Methods: This study examined the antitumor effect of ganetespib in EGFR-mutant non-small cell lung cancer (NSCLC) cells and experimentally established EGFR-tyrosine kinase inhibitor (TKI)-resistant cells harboring various resistance mechanisms, including EGFR T790M mutation, met proto-oncogene amplification, and epithelial-mesenchymal transition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13283DOI Listing
April 2019
3 Reads

Retrospective comparison of stereotactic body radiotherapy versus intensity-modulated radiotherapy for stage III ultra-central squamous non-small-cell lung cancer.

Future Oncol 2019 Apr 5. Epub 2019 Apr 5.

Department of Radiation Oncology, The Fifth Medical Center of Chinese PLA General Hospital, No. 8 East Road, Fengtai District, Beijing 100071, People's Republic of China.

Aim: To analyze the efficacy and toxicity of stereotactic body radiotherapy (SBRT) versus intensity-modulated radiotherapy (IMRT) in stage III patients with ultra-central squamous non-small-cell lung cancer (sqNSCLC).

Methods: Forty-four stage III patients with ultra-central sqNSCLC receiving SBRT (n = 15) or IMRT (n = 29) between December 2014 and August 2017 were reviewed.

Results: At a median follow-up of 16. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0061DOI Listing
April 2019
4 Reads

Interstitial Lung Disease Induced by Crizotinib in Non-Small-Cell Lung Cancer.

Acta Med Port 2019 Mar 29;32(3):236-239. Epub 2019 Mar 29.

Serviço de Medicina Interna. Hospital Prof Doutor Fernando da Fonseca. Amadora. Portugal.

The treatment of advanced non-small-cell lung cancer shifted with the development of molecular-targeted therapies, like the tyrosine kinase inhibitors. One example of tyrosine kinase inhibitors is crizotinib, an anaplastic lymphoma tyrosine kinase inhibitor, which targets an echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase gene fusion. This mutation is found in only 2% to 7% of non-small-cell lung cancer cases. Read More

View Article

Download full-text PDF

Source
https://www.actamedicaportuguesa.com/revista/index.php/amp/a
Publisher Site
http://dx.doi.org/10.20344/amp.9456DOI Listing
March 2019
3 Reads

Efficacy of carboplatin plus S-1 for the treatment of non-small cell lung cancer: A protocol for a systematic review of randomized controlled trial.

Medicine (Baltimore) 2019 Apr;98(14):e15099

Department of Respiratory Medicine, The Affiliated Hongqi Hospital of Mudanjiang Medical University, Mudanjiang.

Background: Non-small cell lung cancer (NSCLC) is the most common lung cancer. Numerous clinical studies have reported that the combination of carboplatin and S-1 (CS) can be used to treat NSCLC effectively. However, no systematic review has been conducted to assess its efficacy and safety for NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000015099DOI Listing
April 2019
6 Reads

Reliability of PD-L1 assays using small tissue samples compared with surgical specimens.

Medicine (Baltimore) 2019 Apr;98(14):e14972

Department of Internal Medicine.

Programmed death ligand 1 (PD-L1) immunohistochemistry (IHC) assays are widely used for complementary or companion diagnostic purposes during treatment with immune checkpoint inhibitors. However, limited information is available on the clinical reliability of the PD-L1 IHC assay using small biopsy samples.Participants included 46 patients with nonsmall cell lung cancer who underwent PD-L1 testing using 3 PD-L1 IHC assays (22C3, SP142, and SP263) for both small biopsy samples and surgical specimens from November 2017 to June 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014972DOI Listing
April 2019
1 Read
5.723 Impact Factor